Journal Watch · Diabetes Care · 2026

GLP-1s Versus DPP-4s and Risk of Dementia in Patients Requiring Hemodialysis: A Target Trial Emulation Study.

DPP-4s) may be a promising therapy to reduce the risk of dementia.

Le D, Kilpatrick M, Kraft WK et al.Diabetes Care3 min readPharma relevance 95/100

DOI: 10.2337/dc25-1836PMID: 41232069Study type: clinical study

TL;DR

DPP-4s) may be a promising therapy to reduce the risk of dementia.

Key findings

  • GLP-1s were also associated with an increased risk of ketoacidosis (sHR 1.52, 95% CI 1.14-2.02; 2-year cumulative incidence: 3.1% vs.
  • 2.2%).<h4>Conclusions</h4>In patients with diabetes requiring hemodialysis, GLP-1s (vs.
  • DPP-4s) may be a promising therapy to reduce the risk of dementia.

Numbers at a glance (from the abstract)

63%95%10.2%11.2%3.1%2.2%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

After IPTW, the average individual was 63 years old, 63% were White, and mean BMI was 31 kg/m2. The median (interquartile interval) follow-up was 1.5 (0.6-2.9) years, and 2,014 patients received a dementia diagnosis. In the intention-to-treat analysis, the IPTW-sHR for dementia was 0.82 (95% CI 0.67-0.98), and after 2 years of follow-up, the cumulative incidence of dementia was 10.2% on GLP-1s vs 11.2% on DPP-4s. As-treated and subgroup analyses were consistent.

Full abstract (original)

Background: <h4>Objective</h4>Glucagon-like peptide 1 agonists (GLP-1s) compared with dipeptidyl peptidase 4 inhibitors (DPP-4s) are associated with reduced risk of dementia in the general population with diabetes, but whether this association is true for patients requiring hemodialysis is unknown.<h4>Research design and methods</h4>Using the U.S. Renal Data System and Medicare Parts A, B, and D claims data from 2011 to 2021, we used the active comparator, new-user design to evaluate incident dementia comparing GLP-1s versus DPP-4s among individuals with both diabetes and hemodialysis dependence. We used inverse probability of treatment weights (IPTW) to balance baseline characteristics and Fine-Gray models to estimate subdistribution hazard ratios (sHRs) accounting for competing risks of death and kidney transplantation. We estimated intention-to-treat and as-treated effects.<h4>Results</h4>We identified 3,619 GLP-1 users and 11,502 DPP-4 users.

What they did: After IPTW, the average individual was 63 years old, 63% were White, and mean BMI was 31 kg/m2. The median (interquartile interval) follow-up was 1.5 (0.6-2.9) years, and 2,014 patients received a dementia diagnosis. In the intention-to-treat analysis, the IPTW-sHR for dementia was 0.82 (95% CI 0.67-0.98), and after 2 years of follow-up, the cumulative incidence of dementia was 10.2% on GLP-1s vs 11.2% on DPP-4s. As-treated and subgroup analyses were consistent.

Results & conclusions: GLP-1s were also associated with an increased risk of ketoacidosis (sHR 1.52, 95% CI 1.14-2.02; 2-year cumulative incidence: 3.1% vs. 2.2%).<h4>Conclusions</h4>In patients with diabetes requiring hemodialysis, GLP-1s (vs. DPP-4s) may be a promising therapy to reduce the risk of dementia.

Abstract © the authors / Diabetes Care (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.2337/dc25-1836 · PubMed 41232069.

Why it matters for pharma & biotech

  • Directly relevant to teams in metabolic / GLP-1 therapeutics, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: metabolic / GLP-1 therapeutics · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Diabetes Care study find?

DPP-4s) may be a promising therapy to reduce the risk of dementia.

What type of study is this?

It is a clinical study, published in Diabetes Care in 2026. After IPTW, the average individual was 63 years old, 63% were White, and mean BMI was 31 kg/m2.

Where can I read the original paper?

The original is at the publisher via DOI 10.2337/dc25-1836. PubMed ID: 41232069. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Le D, Kilpatrick M, Kraft WK et al.. GLP-1s Versus DPP-4s and Risk of Dementia in Patients Requiring Hemodialysis: A Target Trial Emulation Study.. Diabetes Care (2026). DOI: 10.2337/dc25-1836.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/glp-1s-versus-dpp-4s-and-risk-of-dementia-in-patients-requiring-hemodial-251836/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides